Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GK01 in Advanced Solid Tumors
NCT07351903Phase 1Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GK01 in solid tumor, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Safety and Tolerability at 2 years. Started Oct 2025; status: recruiting.
02
Drugs
GK01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07351903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07351903.